Clinical Trials Browser

Phase 3 × Sunitinib × 90 days × Clear all

Carcinoma, Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Neoplasms by Site, Urologic Neoplasms

NCT07218926 2026-04-03

A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy

Phase 3 Recruiting

450 enrolled

GastrointestinalSarcoma

Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors

NCT05477576 2026-03-30

ACTION-1

Phase 3 Recruiting

338 enrolled

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT02811861 2026-02-23

CLEAR

Phase 3 Active not recruiting

1,069 enrolled 12 charts 2 FDA

Genitourinary

Carcinoma, Renal Cell

NCT03673501 2026-02-05

INTRIGUE

Phase 3 Active not recruiting

453 enrolled 20 charts

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT05208047 2026-02-04

(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors

Phase 3 Active not recruiting

442 enrolled

GastrointestinalSarcoma

Neoplasm Metastasis, Gastrointestinal Stromal Tumors

NCT02853331 2026-02-02

KEYNOTE-426

Phase 3 Completed

861 enrolled 24 charts 2 FDA

Genitourinary

Carcinoma, Renal Cell

NCT03768063 2026-01-29

IMbrella B

Phase 3 Active not recruiting

1,000 enrolled

Tumor-Agnostic

Neoplasms

Clinical Trials

Savolitinib vs. Sunitinib in MET-driven PRCC.

A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy

ACTION-1

CLEAR

INTRIGUE

(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors

KEYNOTE-426

IMbrella B